Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (NASDAQ: SLP) is a leading developer of modeling and simulation software and consulting services that support drug discovery, development research, and regulatory submissions. The company collaborates with pharmaceutical organizations to implement a data-driven, strategic modeling methodology that begins in early discovery stages, extends through preclinical and clinical development, and continues into clinical trials and post-approval phases.
Simulations Plus, through its subsidiaries Cognigen Corporation and DILIsym Services, offers a suite of top-ranked, user-friendly software solutions. These include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, PKPlus™, and more. These tools bridge data mining and compound library screening with QSAR models and PBPK/TK modeling and simulation in both animals and humans. The company's quantitative systems pharmacology approaches are widely recognized and licensed by regulatory agencies globally.
In addition to software development, Simulations Plus provides consulting and contract research services to the pharmaceutical industry. The company’s operations are divided into two primary segments: software and services. The software segment generates the majority of the company’s revenue.
Over the past 20 years, Simulations Plus has consistently partnered with clients to reduce costs and accelerate research timelines. The company’s innovative technology and methodologies have earned it a reputation as a reliable partner in the pharmaceutical industry.
Latest News: Simulations Plus continues to make headlines with its innovative solutions and strategic partnerships. Stay updated with the latest developments and achievements of Simulations Plus on our news section.
Simulations Plus (NASDAQ: SLP) is set to announce its fourth quarter and full year financial results for fiscal year 2022, ending August 31, 2022, following market closure on October 26, 2022. The company will host a conference call at 5:00 PM ET that day, inviting all interested parties to participate. The call can be accessed via registration or by calling in. Simulations Plus has been a key player in the biosimulation market for over 25 years, providing essential software and consulting services for drug discovery and regulatory submissions.
Simulations Plus, Inc. (Nasdaq: SLP) has announced that CEO Shawn O’Connor will present at the Sidoti Fall Small Cap Investor Conference on September 22, 2022, at 10:45 a.m. ET. The conference will be held virtually on September 21-22, 2022, where O’Connor will engage with investors throughout the day. The presentation will be webcast live and available for replay on the Simulations Plus investor page. For additional details about the conference, visit the conference website or contact Brian Siegel at Hayden IR.
Simulations Plus, a leader in biosimulation software, will present at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 2:00 p.m. ET. CEO Shawn O’Connor will discuss the company's advancements in modeling and simulation for pharmaceutical safety and efficacy. The session will be webcast live and available for replay on the Simulations Plus website. Established for over 25 years, Simulations Plus provides innovative solutions to major pharmaceutical and regulatory agencies worldwide.
Simulations Plus has launched ILDsym™ version 1A, a quantitative systems pharmacology modeling software aimed at enhancing therapy development for Interstitial Lung Disease (ILD)
Simulations Plus (NASDAQ: SLP) announces a collaboration with a large pharmaceutical company to enhance its ADMET Predictor® platform. The partner will provide tens of thousands of proprietary pKa measurements to improve prediction accuracy and extend chemical coverage. This initiative aims to reinforce ADMET Predictor as the leading property prediction tool in drug discovery, leveraging advanced machine learning techniques. The collaboration is expected to significantly advance predictive modeling within the pharmaceutical sector.
Simulations Plus (NASDAQ: SLP) announced the presentation of five scientific posters at the PAGE conference in Ljubljana, Slovenia, from June 28 to July 1, 2022. The conference gathered over 600 scientists focused on data analysis through a population approach. Dr. Jonathan Chauvin emphasized the importance of the event for discussing advancements in modeling and simulation, particularly the MonolixSuite platform. New developments presented include algorithms aimed at enhancing NLME modeling, contributing to the increasing adoption of MonolixSuite.
Simulations Plus (NASDAQ: SLP) has launched a Concierge Program aimed at fostering strategic partnerships with pharmaceutical companies and contract research organizations. This initiative is designed to enhance customer support through regular communication and collaboration, helping clients to expedite their development programs. Notable successes have been reported, including tailored training for regulatory scientists and customized software solutions across North America, Europe, and South America. The program demonstrates SLP's commitment to understanding clients' evolving needs in the pharmaceutical landscape.
Simulations Plus, Inc. (Nasdaq: SLP) reported a 17% total revenue growth for Q3 fiscal 2022, reaching $15.0 million. The software revenue rose by 16% to $9.7 million, while services revenue grew by 19% to $5.3 million. Diluted EPS increased by 11% to $0.20, with a net income of $4.1 million. The company reiterated its full-year revenue guidance of $52-53 million and announced a quarterly dividend of $0.06 per share, payable August 1, 2022.
Simulations Plus, Inc. (Nasdaq: SLP) reported record attendance at the 2022 Pharmacometrics Spring School, with 936 participants from over 50 countries. The event featured workshops on model-informed drug development and clinical trial simulations using the MonolixSuite and PKanalix platforms, both offered free to attendees. Dr. Jonathan Chauvin highlighted strong community interest which supports the company's position as a leader in modeling and simulation software. The company aims to continue these workshops in 2023.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
What does Simulations Plus, Inc. do?
What are the main products of Simulations Plus?
How does Simulations Plus support drug development?
Who uses Simulations Plus technology?
What are the primary segments of Simulations Plus’ operations?
Which subsidiaries are part of Simulations Plus?
How long has Simulations Plus been in operation?
Where is Simulations Plus headquartered?
Does Simulations Plus offer consulting services?
How can I stay updated on Simulations Plus’ latest news?
